Lifesci Capital began coverage on shares of Hemab Therapeutics (NASDAQ:COAG – Get Free Report) in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage set an “outperform” rating and a $65.00 price target on the stock. Lifesci Capital‘s price objective indicates a potential upside of 32.60% from the company’s previous close.
A number of other equities analysts also recently commented on COAG. Rodman & Renshaw began coverage on shares of Hemab Therapeutics in a research note on Monday, October 12th. They issued a “buy” rating and a $56.00 target price on the stock. Jefferies Financial Group upped their target price on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Weiss Ratings lowered Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 25th. JPMorgan Chase & Co. started coverage on Hemab Therapeutics in a report on Thursday, October 15th. They set an “overweight” rating and a $70.00 target price on the stock. Finally, Wedbush boosted their price target on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.
View Our Latest Research Report on Hemab Therapeutics
Hemab Therapeutics Stock Performance
NASDAQ:COAG opened at $49.02 on Monday. The stock has a market cap of $2.29 billion and a price-to-earnings ratio of -1.98. The company has a 50-day moving average price of $37.50. Hemab Therapeutics has a 12-month low of $23.00 and a 12-month high of $55.42.
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, equities analysts predict that Hemab Therapeutics will post -3.10 earnings per share for the current year.
Hedge Funds Weigh In On Hemab Therapeutics
A number of institutional investors have recently added to or reduced their stakes in COAG. Citadel Advisors LLC purchased a new position in Hemab Therapeutics in the 2nd quarter valued at about $19,226,000. Braidwell LP purchased a new stake in shares of Hemab Therapeutics during the second quarter worth about $5,877,000. State Street Corp purchased a new stake in shares of Hemab Therapeutics during the second quarter worth about $2,825,000. Opaleye Management Inc. acquired a new position in shares of Hemab Therapeutics in the second quarter worth about $1,750,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Hemab Therapeutics in the second quarter worth about $688,000.
Hemab Therapeutics Company Profile
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.
Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.
Recommended Stories
- Five stocks we like better than Hemab Therapeutics
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Hemab Therapeutics Right Now?
Before you consider Hemab Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Hemab Therapeutics wasn’t on the list.
While Hemab Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
